Drug intelligence / Profile preview

SporeVax-C. perfringens

Development stage: Preclinical
Lead developer: SporeGen
Modality: Vaccines & Immunotherapeutics
Administration: Mucosal

Overview

SporeVax-C. perfringens is a mucosal vaccine candidate developed by SporeGen for the prevention of Clostridium perfringens infection. The vaccine platform utilizes Bacillus subtilis spores as a delivery vehicle to present specific C. perfringens antigens to the mucosal immune system. This spore-based approach is designed to induce both local mucosal and systemic immunity, providing protection against the pathogen. The use of spores offers advantages in terms of stability and natural adjuvant properties, potentially eliminating the need for cold-chain storage. The project is currently in the preclinical stage of development.

Other names: SporeVax - Clostridium perfringens

Targets

Hla (Staphylococcus aureus alpha toxin)

Beyond the preview

Go deeper on SporeVax-C. perfringens.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SporeVax-C. perfringens.

Explore the full profile